Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug
2016 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug
Tzikas, A.; Shakir, S.; Gafoor, S.; Omran, H.; Berti, S.; Santoro, G. & Kefer, J. et al. (2016)
EuroIntervention, 11(10) pp. 1170-1179. DOI: https://doi.org/10.4244/EIJY15M01_06
Documents & Media
Details
- Authors
- Tzikas, Apostolos; Shakir, Samera; Gafoor, Sameer; Omran, Heyder; Berti, Sergio; Santoro, Gennaro; Kefer, Joelle; Landmesser, Ulf; Nielsen-Kudsk, Jens Erik; Cruz-Gonzalez, Ignacio; Sievert, Horst; Tichelbäcker, Tobias ; Kanagaratnam, Prapa; Nietlispach, Fabian; Aminian, Adel; Kasch, Friederike; Freixa, Xavier; Danna, Paolo; Rezzaghi, Marco; Vermeersch, Paul; Stock, Friederike; Stolcova, Miroslava; Costa, Marco; Ibrahim, Reda; Schillinger, Wolfgang ; Meier, Bernhard; Park, Jai-Wun
- Abstract
- Aims: To investigate the safety, feasibility, and efficacy of left atrial appendage occlusion (LAAO) with the AMPLATZER Cardiac Plug (ACP) for stroke prevention in patients with atrial fibrillation (AF). Methods and results: Data from consecutive patients treated in 22 centres were collected. A total of 1,047 patients were included in the study. Procedural success was 97.3%. There were 52 (4.97%) periprocedural major adverse events. Follow-up was complete in 1,001/1,019 (98.2%) of successfully implanted patients (average 13 months, total 1,349 patient-years). One-year all-cause mortality was 4.2%. No death at follow-up was reported as device-related. There were nine strokes (0.9%) and nine transient ischaemic attacks (0.9%) during follow-up. The annual rate of systemic thromboembolism was 2.3% (31/1,349 patient-years), which is a 59% risk reduction. There were 15 major bleedings (1.5%) during follow-up. The annual rate of major bleeding was 2.1% (28/1,349 patient-years), which is a 61% risk reduction. Patients with single LAAO on aspirin monotherapy or no therapy and longer follow-up had fewer cerebral and fewer bleeding events. Conclusions: In this multicentre study, LAAO with the ACP showed high procedural success and a favourable outcome for the prevention of AF-related thromboembolism. Modification in antithrombotic therapy after LAAO may result in reduction of bleeding events.
- Issue Date
- 2016
- Status
- published
- Publisher
- Europa Edition
- Journal
- EuroIntervention
- ISSN
- 1774-024X
- ISSN
- 1969-6213; 1774-024X